Allan R. Li
- Pulmonary and Respiratory Medicine top 1%
- Oncology top 2%
- Molecular Biology top 10%
- Cancer Research top 5%
- Pathology and Forensic Medicine top 10%
- Co-authors
- Marc LadanyiMark G. KrisWilliam PaoMaureen F. ZakowskiVincent A. MillerGregory J. RielyNaiyer A. RizviEnnapadam Venkatraman
- Topics
- Lung Cancer Treatments and Mutations (6 papers)HER2/EGFR in Cancer Research (3 papers)Colorectal Cancer Treatments and Studies (3 papers)
- Partner nations
- United States
In The Last Decade
Allan R. Li
7 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 70
- Pulmonary and Respiratory Medicine 1.8k
- Oncology 1.6k
- Molecular Biology 755
- Cancer Research 496
- Pathology and Forensic Medicine 145
Countries citing papers authored by Allan R. Li
This map shows the geographic impact of Allan R. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan R. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan R. Li more than expected).
Fields of papers citing papers by Allan R. Li
This network shows the impact of papers produced by Allan R. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan R. Li. The network helps show where Allan R. Li may publish in the future.
Co-authorship network of co-authors of Allan R. Li
This figure shows the co-authorship network connecting the top 25 collaborators of Allan R. Li. A scholar is included among the top collaborators of Allan R. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan R. Li. Allan R. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 202 | |
| 2 | 164 | |
| 3 | 237 | |
| 4 | Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitorsbreakdown → | 664 |
| 5 | Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinibbreakdown → | 623 |
| 6 | 127 | |
| 7 | 272 |
About Allan R. Li
Allan R. Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology, having authored 7 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Oncology (1.6k citations), Pulmonary and Respiratory Medicine (1.8k citations) and Cancer Research (496 citations). Allan R. Li has collaborated with scholars based in United States. Frequent co-authors include Marc Ladanyi, Mark G. Kris, William Pao, Maureen F. Zakowski, Vincent A. Miller, Gregory J. Riely, Naiyer A. Rizvi, Ennapadam Venkatraman, DuyKhanh Pham and Yixuan Gong. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and Modern Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.